The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing. Click to read.

Beam’s therapy employs base editing to perform an in vivo correction of the mutation at the root of the inherited disease. The Phase 1/2 test is designed with two parts: Part A is assessing the ...

The Cambridge-based base editing company, Beam Therapeutics, has announced initial safety and efficacy data from its Phase I/II trial of BEAM-302, establishing clinical proof-of-concept as a ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Beam is a pioneer of the base-editing approach to gene-editing, which can be used to convert one nucleotide base into another without cutting both strands of DNA, unlike other technologies like ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...

Beam Therapeutics shares were 14% lower, at $24.60, after the company priced an underwritten offering with proceeds of $500 million. The biotechnology company said it is offering 16.2 million shares ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

In this case, Beam aims to treat a genetic condition called alpha-1 antitrypsin deficiency, or AATD, by fixing the DNA misspelling at the disease’s root. Delivered into the liver by tiny globules of ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...